Important note: Information in this article was accurate in 2001. The state of the art may have changed since the publication date.
PRNewswire - December 12, 2001
The Company will hold a conference call to discuss the latebreaker on Tuesday, November 18 at 11:00am Central time (12:00pm Eastern time). The call will be hosted by Bill Young, Chairman and CEO of ViroLogic, and Dr. Richman. To participate, please dial 800-360-9865 ten minutes prior to the start of the call. A replay of the call will be available beginning at 1:00pm Central time (2:00pm Eastern time) by dialing 800-428-6051 and entering passcode 218854. International callers dial 973-709-2089.
In addition to the latebreaker presentation, three additional studies highlighting ViroLogic's products will be presented:
Date: Tuesday, December 18, 1:30pm - 3:00pm Title: Measurement of Drug Susceptibility and Replication Capacity of Six Different HIV-1 Subtypes: A, B, C, D, F, and G. Presenter: Dr. Nicholas Hellmann, VP of Clinical Research, ViroLogic Location: Exhibit Hall
Date: Tuesday, December 18, 1:30pm - 3:00pm Title: Impact of M184V/I Mutation on HIV Phenotypic Resistance to Nucleoside Analogs (nRTIs) in nRTI-Experienced Patients Presenter: Dr. Nancy Shulman, Stanford University Location: Exhibit Hall
Date: Tuesday, December 18, 3:00pm - 4:30pm Title: A Rapid Multi-Functional HIV-1 Entry Assay for Measuring Drug Susceptibility, Co-Receptor Tropism, and Antibody Neutralization. Presenter: Chris Petropoulos, VP of Research and Development, ViroLogic Location: Exhibit Hall
ViroLogic is also hosting a satellite symposium preceding ICAAC, titled "Making Individualized HIV Treatment a Reality." The symposium breakfast program will be held on Sunday, December 16 at the Hyatt Regency Chicago, 151 East Wacker Drive, Regency Ballroom B, from 8:00am to 9:20am. Featured speakers will be Dr. Robert Schooley, Dr. Douglas Richman and Dr. Richard Haubrich. To register, please call 888-527-7342 or visit http://www.phenosense.com/ICAAC.
ICAAC attendees are invited to visit the Company's exhibit booth #1041.
About ViroLogic
ViroLogic is a biotechnology company advancing the fields of individualized medicine and pharmacogenomics, helping to make them realities in healthcare around the world today. The Company discovers, develops and markets innovative products to guide and improve treatment of serious viral diseases such as AIDS and hepatitis. Its leading expertise in virology, molecular biology, clinical research, engineering, information systems, and quality assurance has resulted in technology to assess drug resistance and susceptibility in viruses that cause these diseases, which affect millions of people worldwide.
The Company's current products are designed to optimize HIV/AIDS treatment regimens, providing physicians with important information to help select appropriate drugs for their patients and leading to better outcomes and reduced costs. These products are also being used by nearly every major pharmaceutical company working to develop new and improved antiviral therapeutics that can be more effective in an increasingly drug-resistant environment.
Certain statements in this press release are forward-looking, including statements relating to the Company's product development efforts. These forward-looking statements are subject to risks and uncertainties and other factors, which may cause actual results to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. These risks and uncertainties include, but are not limited to, whether ViroLogic's products will achieve market acceptance, whether payers will authorize reimbursement for our products, whether we will be able to expand our sales and marketing capabilities, whether the FDA or any other agency will decide to regulate our products or services, whether we will encounter problems or delays in automating our process, whether we will successfully introduce new products using our PhenoSense technology, whether intellectual property underlying our technology is adequate, whether we are able to build brand loyalty, whether we will be able to raise sufficient capital and other risks and uncertainties detailed from time to time in our reports to the Securities and Exchange Commission, including our report on Form 10-K for the year ended December 31, 2000.
011212
PR011220
Copyright © 2001 - PRNewswire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through PRNewswire, Permissions, 810 Seventh Ave., 32nd Floor, New York, NY 10019 http://www.PRNewswire.com.
AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, iMetrikus, Inc., the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2001. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2001. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .